Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lapatinib in HER2+ Breast Cancer
NCT00206427Phase 2Completed
- Sponsor
- Baylor Breast Care Center
- Start
- Aug 2004
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in HER2-positive breast cancer, sponsored by Baylor Breast Care Center. Primary endpoint: Clinical Response at 6 weeks. Started Aug 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00206427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206427.